汉森制药(002412)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002412 汉森制药

已收盘 10-10 15:00:00

{"stockData":{"symbol":"002412","market":"SZ","secType":"STK","nameCN":"汉森制药","latestPrice":6.43,"timestamp":1760079825000,"preClose":6.33,"halted":0,"volume":8562922,"delay":0,"changeRate":0.0158,"floatShares":498000000,"shares":503000000,"eps":0.3742,"marketStatus":"已收盘","change":0.1,"latestTime":"10-10 15:00:00","open":6.33,"high":6.45,"low":6.3,"amount":54799000,"amplitude":0.0237,"askPrice":6.43,"askSize":52,"bidPrice":6.42,"bidSize":262,"shortable":0,"etf":0,"ttmEps":0.3742,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1760319000000},"marketStatusCode":5,"adr":0,"adjPreClose":6.33,"symbolType":"stock","openAndCloseTimeList":[[1760059800000,1760067000000],[1760072400000,1760079600000]],"highLimit":6.96,"lowLimit":5.7,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":503200000,"isCdr":false,"pbRate":1.41,"roa":"--","peRate":17.183324,"roe":"3.07%","epsLYR":0.4377,"committee":0.152772,"marketValue":3236000000,"turnoverRate":0.0172,"status":0,"floatMarketCap":3201000000},"requestUrl":"/m/hq/s/002412","defaultTab":"news","newsList":[{"id":"2574972941","title":"股市必读：汉森制药（002412）9月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2574972941","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574972941?lang=zh_cn&edition=full","pubTime":"2025-10-09 04:10","pubTimestamp":1759954225,"startTime":"0","endTime":"0","summary":"截至2025年9月30日收盘，汉森制药报收于6.36元，下跌0.62%，换手率1.07%，成交量5.32万手，成交额3390.1万元。董秘最新回复投资者： 你好，请问作为儿童药的四磨汤口服液是否有望入选新版的国家基药目录，还有天麻醒脑胶囊，谢谢董秘： 尊敬的投资者您好，目前未见调整新版国家基药目录的官方信息。当日关注点来自交易信息汇总：9月30日主力资金净流出330.36万元，占总成交额9.74%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025100900001172.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002412","BK0039"],"gpt_icon":0},{"id":"2570026659","title":"汉森制药：中药新药苁蓉颗粒处于中试阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2570026659","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570026659?lang=zh_cn&edition=full","pubTime":"2025-09-26 08:51","pubTimestamp":1758847875,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)09月25日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司今年的研发计划里面，创新药占比多少？谢谢汉森制药回复：尊敬的投资者您好，公司在产品研发方面，中药新药苁蓉颗粒正处于工艺中试放大研究阶段。具体情况请参考公司2024年度报告。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092600005457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412","BK0239","BK0039","BK0028"],"gpt_icon":0},{"id":"2569754943","title":"汉森制药：截至2025年8月29日股东总数为23580人","url":"https://stock-news.laohu8.com/highlight/detail?id=2569754943","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569754943?lang=zh_cn&edition=full","pubTime":"2025-09-23 09:01","pubTimestamp":1758589283,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)09月22日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司9月20日的股东人数是多少？谢谢汉森制药回复：投资者您好，公司可在互动易平台回复非定期报告时点的月末股东人数，截至2025年8月29日，公司含信用账户合并股东名册的股东总数为：23580人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092300006001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412","BK0239","BK0039","BK0028"],"gpt_icon":0},{"id":"2567615732","title":"股市必读：汉森制药(002412)股东户数2.36万户，较上期减少3.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2567615732","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567615732?lang=zh_cn&edition=full","pubTime":"2025-09-15 03:23","pubTimestamp":1757877792,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘，汉森制药报收于6.74元，下跌1.03%，换手率2.68%，成交量13.33万手，成交额8946.05万元。来自公司公告汇总：汉森制药将于2025年9月19日参加湖南辖区上市公司投资者网上集体接待日暨半年度业绩说明会。股本股东变化股东户数变动截至2025年8月29日，公司股东户数为2.36万户，较7月31日减少838户，减幅为3.43%。户均持股数量由上期的2.06万股增加至2.13万股，户均持股市值为14.32万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091500001063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412","BK0239","BK0039","BK0028"],"gpt_icon":0},{"id":"2566943211","title":"汉森制药：截至2025年8月29日股东总数为23580人","url":"https://stock-news.laohu8.com/highlight/detail?id=2566943211","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566943211?lang=zh_cn&edition=full","pubTime":"2025-09-12 08:52","pubTimestamp":1757638329,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)09月11日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，请问，贵公司截止9月10日股东人数是多少？谢谢！汉森制药回复：投资者您好，公司可在互动易平台回复非定期报告时点的月末股东人数，截至2025年8月29日，公司含信用账户合并股东名册的股东总数为：23580人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091200005779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412","BK0028","BK0039","BK0239"],"gpt_icon":0},{"id":"2566647675","title":"汉森制药：恩格列净片目前已生产销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2566647675","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566647675?lang=zh_cn&edition=full","pubTime":"2025-09-10 08:45","pubTimestamp":1757465115,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药09月09日在投资者关系平台上答复投资者关心的问题。还是需要拿到批文后才能生产销售？汉森制药回复：尊敬的投资者您好，10mg规格的恩格列净片目前已生产销售，适用于治疗2型糖尿病；以及用于症状性慢性心力衰竭成人患者，降低因心力衰竭住院的风险。产品对公司下半年的业绩的影响尚不确定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091000006910.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412","BK0028","BK0039","BK0239"],"gpt_icon":0},{"id":"2565522492","title":"股市必读：汉森制药(002412)股东户数2.36万户，较上期减少3.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2565522492","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565522492?lang=zh_cn&edition=full","pubTime":"2025-09-08 04:27","pubTimestamp":1757276832,"startTime":"0","endTime":"0","summary":"截至2025年9月5日收盘，汉森制药报收于6.85元，上涨1.03%，换手率2.0%，成交量9.94万手，成交额6746.0万元。来自股本股东变化：截至8月29日股东户数环比减少3.43%，户均持股上升至2.13万股，筹码集中度提升。交易信息汇总资金流向9月5日主力资金净流出377.84万元；游资资金净流入184.23万元；散户资金净流入193.61万元。股本股东变化股东户数变动截至2025年8月29日，汉森制药股东户数为2.36万户，较7月31日减少838.0户，减幅为3.43%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090800001140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412","BK0028","BK0039","BK0239"],"gpt_icon":0},{"id":"2565561055","title":"汉森制药(002412)8月29日股东户数2.36万户，较上期减少3.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2565561055","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565561055?lang=zh_cn&edition=full","pubTime":"2025-09-05 17:28","pubTimestamp":1757064521,"startTime":"0","endTime":"0","summary":"证券之星消息，近日汉森制药披露，截至2025年8月29日公司股东户数为2.36万户，较7月31日减少838.0户，减幅为3.43%。在中药行业个股中，汉森制药股东户数低于行业平均水平，截至8月29日，中药行业平均股东户数为5.29万户。从股价来看，2025年7月31日至2025年8月29日，汉森制药区间跌幅为4.28%，在此期间股东户数减少838.0户，减幅为3.43%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090500029023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412","BK0028","BK0039","BK0239"],"gpt_icon":0},{"id":"2564568143","title":"汉森制药：截至2025年8月29日股东总数为23580人","url":"https://stock-news.laohu8.com/highlight/detail?id=2564568143","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564568143?lang=zh_cn&edition=full","pubTime":"2025-09-03 11:37","pubTimestamp":1756870625,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)09月02日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，请问，贵公司截止8月31日股东人数是多少？谢谢！汉森制药回复：投资者您好，截至2025年8月29日，公司含信用账户合并股东名册的股东总数为：23580人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090300014852.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","002412","BK0239","BK0028"],"gpt_icon":0},{"id":"2564354826","title":"汉森制药：四磨汤口服液在多个集采项目中获得中选资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2564354826","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564354826?lang=zh_cn&edition=full","pubTime":"2025-09-02 08:46","pubTimestamp":1756773972,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药09月01日在投资者关系平台上答复投资者关心的问题。投资者提问：9月国家医保谈判和集采展开，贵公司主打产品之一儿童药四磨汤口服液是否有希望中标？谢谢汉森制药回复：尊敬的投资者您好，公司产品四磨汤口服液在京津冀“3+N”联盟药品集中采购项目和福建第四批集中带量采购项目、江苏省第五轮药品集中带量采购中获得中选资格,在广东联盟金莲花等中成药集中带量采购项目中获得中选限量可按需采购资格。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090200006928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0039","002412","BK0028"],"gpt_icon":0},{"id":"2562610497","title":"汉森制药：以天麻醒脑胶囊为核心打造现代高原药第一品牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2562610497","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562610497?lang=zh_cn&edition=full","pubTime":"2025-08-27 08:48","pubTimestamp":1756255697,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问：公司股价近十年表现一直很不好，同时在创新药研发方面投入不足，可能面临市场竞争加剧的风险客户，难道一直守着四磨汤口服液过日子吗？汉森制药回复：尊敬的投资者您好，公司立足中成药主业，一方面持续做大四磨汤口服液市场，另一方面以天麻醒脑胶囊为核心打造现代高原药第一品牌，同时推进其他优质产品成长；研发上，中药新药苁蓉颗粒正处工艺中试放大研究阶段。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082700011991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412","BK0039","BK0239","BK0028"],"gpt_icon":0},{"id":"2562243505","title":"汉森制药(002412.SZ)发布上半年业绩，归母净利润6853.84万元，下降31.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562243505","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562243505?lang=zh_cn&edition=full","pubTime":"2025-08-25 18:42","pubTimestamp":1756118533,"startTime":"0","endTime":"0","summary":"智通财经APP讯，汉森制药(002412.SZ)发布2025年半年度报告，该公司营业收入为5.09亿元，同比增长5.91%。归属于上市公司股东的净利润为6853.84万元，同比减少31.80%。归属于上市公司股东的扣除非经常性损益的净利润为6476.95万元，同比减少31.72%。基本每股收益为0.1362元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334590.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002412"],"gpt_icon":0},{"id":"2562711295","title":"股市必读：汉森制药（002412）8月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2562711295","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562711295?lang=zh_cn&edition=full","pubTime":"2025-08-25 09:19","pubTimestamp":1756084748,"startTime":"0","endTime":"0","summary":"截至2025年8月22日收盘，汉森制药报收于6.84元，下跌0.73%，换手率2.14%，成交量10.67万手，成交额7257.7万元。如有相关事项，公司将根据相关规定及时履行信息披露义务。董秘： 投资者您好，公司可在互动易平台回复非定期报告时点的月末股东人数，截至2025年7月31日，公司含信用账户合并股东名册的股东总数为：24418人。交易信息汇总8月22日，汉森制药的资金流向显示主力资金净流入980.03万元；游资资金净流出216.11万元；散户资金净流出763.92万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082500002788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","002412","BK0239","BK0028"],"gpt_icon":0},{"id":"2561447194","title":"汉森制药：中药新药苁蓉颗粒处于工艺中试放大研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2561447194","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561447194?lang=zh_cn&edition=full","pubTime":"2025-08-22 11:36","pubTimestamp":1755833765,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)08月21日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司研发中药新药苁蓉颗粒目前进度如何，在创新药方面是否有新的进展？天麻醒脑胶囊具体是治疗那方面？谢谢汉森制药回复：尊敬的投资者您好，公司在产品研发方面，中药新药苁蓉颗粒正处于工艺中试放大研究阶段。天麻醒脑胶囊，主要功能为滋补肝肾，通络止痛。用于肝肾不足所致头痛头晕，记忆力减退，失眠，反应迟钝，耳鸣，腰酸。具体情况请参考公司2024年度报告。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082200016996.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412","BK0028","BK0039","BK0239"],"gpt_icon":0},{"id":"2559938829","title":"汉森制药：公司将继续聚焦主业，通过提升盈利能力维护投资者信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2559938829","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559938829?lang=zh_cn&edition=full","pubTime":"2025-08-14 08:54","pubTimestamp":1755132852,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药08月13日在投资者关系平台上答复投资者关心的问题。十年多来还没有板块市值的一半高，分红也不怎么样，如何推动公司持续稳定发展、不断创造价值，维护投资人信心，回报投资者？公司将继续聚焦主业，通过提升盈利能力维护投资者信心。感谢您对公司的关注。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081400006001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0039","002412"],"gpt_icon":0},{"id":"2559678802","title":"汉森制药：截至2025年7月31日股东总数为24418人","url":"https://stock-news.laohu8.com/highlight/detail?id=2559678802","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559678802?lang=zh_cn&edition=full","pubTime":"2025-08-13 08:42","pubTimestamp":1755045734,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)08月12日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘：截止8月10日，股东人数是多少？汉森制药回复：投资者您好，公司可在互动易平台回复非定期报告时点的月末股东人数，截至2025年7月31日，公司含信用账户合并股东名册的股东总数为：24418人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081300006308.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0039","BK0239","002412"],"gpt_icon":0},{"id":"2557535819","title":"汉森制药：截至2025年7月31日股东总数为24418人","url":"https://stock-news.laohu8.com/highlight/detail?id=2557535819","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557535819?lang=zh_cn&edition=full","pubTime":"2025-08-05 09:01","pubTimestamp":1754355662,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)08月04日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截至2025年7月31日公司股东人数是多少？谢谢~汉森制药回复：投资者您好，截至2025年7月31日，公司含信用账户合并股东名册的股东总数为：24418人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080500007948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","002412","BK0028","BK0239"],"gpt_icon":0},{"id":"2545140207","title":"汉森制药(002412)5月30日股东户数2.48万户，较上期减少2.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2545140207","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545140207?lang=zh_cn&edition=full","pubTime":"2025-06-24 17:19","pubTimestamp":1750756775,"startTime":"0","endTime":"0","summary":"证券之星消息，近日汉森制药披露，截至2025年5月30日公司股东户数为2.48万户，较4月30日减少620.0户，减幅为2.44%。在中药行业个股中，汉森制药股东户数低于行业平均水平，截至5月30日，中药行业平均股东户数为5.31万户。从股价来看，2025年4月30日至2025年5月30日，汉森制药区间涨幅为8.83%，在此期间股东户数减少620.0户，减幅为2.44%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062400028117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0039","002412","BK0028"],"gpt_icon":0},{"id":"2545499851","title":"汉森制药收盘上涨1.70%，滚动市盈率17.40倍，总市值30.14亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545499851","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545499851?lang=zh_cn&edition=full","pubTime":"2025-06-23 16:41","pubTimestamp":1750668077,"startTime":"0","endTime":"0","summary":"6月23日，汉森制药今日收盘5.99元，上涨1.70%，滚动市盈率PE达到17.40倍，总市值30.14亿元。从行业市盈率排名来看，公司所处的中药行业市盈率平均37.71倍，行业中值27.96倍，汉森制药排名第28位。截至2025年一季报，共有4家机构持仓汉森制药，其中其他2家、QFII1家、基金1家，合计持股数23833.55万股，持股市值14.54亿元。湖南汉森制药股份有限公司的主营业务是传统中成药制剂、化学药、医用制剂的研发、生产和销售。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/23164151240230.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0028","BK0039","BK0239","002412"],"gpt_icon":0},{"id":"2544976351","title":"汉森制药：公司2024年根据新国九条及相关法律法规修订并披露《未来三年（2024-2026年）股东回报规划》","url":"https://stock-news.laohu8.com/highlight/detail?id=2544976351","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544976351?lang=zh_cn&edition=full","pubTime":"2025-06-20 08:33","pubTimestamp":1750379590,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)06月19日在投资者关系平台上答复投资者关心的问题。投资者提问：很多公司都能做到每年分红，为什么贵公司都不能做到每年分红呢？汉森制药回复：尊敬的投资者您好，公司2024年根据新国九条及相关法律法规修订并披露《未来三年（2024-2026年）股东回报规划》，我们将严格执行现金分红规定和承诺，继续努力，为股东创造更多价值。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062000004468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0039","BK0239","002412"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1760141733210,"stockEarnings":[{"period":"1week","weight":0.011},{"period":"1month","weight":-0.0572},{"period":"3month","weight":-0.0228},{"period":"6month","weight":0.1222},{"period":"1year","weight":0.0789},{"period":"ytd","weight":0.0699}],"compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":0.0222},{"period":"3month","weight":0.1102},{"period":"6month","weight":0.2034},{"period":"1year","weight":0.1802},{"period":"ytd","weight":0.1627}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖南汉森制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"23580人(较上一季度减少3.43%)","perCapita":"21113股","listingDate":"2010-05-25","address":"湖南省益阳市赫山区银城大道2688号","registeredCapital":"50320万元","survey":"　　湖南汉森制药股份有限公司的主营业务是生产中药制剂、化学药。公司的主要产品是四磨汤口服液、缩泉胶囊、银杏叶胶囊、天麻醒脑胶囊、愈伤灵胶囊、百贝益肺胶囊、利胆止痛胶囊、胃肠灵胶囊、藿香正气水、玉竹膏、通关藤胶囊、参七心疏胶囊、感冒清热颗粒、人工牛黄甲硝唑胶囊、氢溴酸右美沙芬颗粒、复方氨酚烷胺片、卡托普利片、甲硝唑片、碳酸氢钠片、碘海醇注射液、碘帕醇注射液、泛影葡胺注射液。","listedPrice":35.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.3","shortVersion":"4.35.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"汉森制药(002412)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供汉森制药(002412)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"汉森制药,002412,汉森制药股票,汉森制药股票老虎,汉森制药股票老虎国际,汉森制药行情,汉森制药股票行情,汉森制药股价,汉森制药股市,汉森制药股票价格,汉森制药股票交易,汉森制药股票购买,汉森制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"汉森制药(002412)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供汉森制药(002412)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}